Fuld fokus på terapeutisk vaccine
ExpreS2ion Biotechnologies is featured in a publication by Dansk Biotek today (in Danish). Our CEO, Bent Frandsen, presents one of […]
ExpreS2ion Biotechnologies is featured in a publication by Dansk Biotek today (in Danish). Our CEO, Bent Frandsen, presents one of […]
Check out ExpreS2ion Biotechnologies in this short video. Making a difference within oncology and infectious diseases – and we are […]
Plasmodium falciparum causes the severe form of malaria that has high levels of mortality in humans. Blood-stage merozoites of P. falciparuminvade erythrocytes, […]
The quest to develop an effective malaria vaccine remains a major priority in the fight against global infectious disease. An […]
Plasmodium falciparum reticulocyte-binding protein homolog 5 (PfRH5) is a leading asexual blood-stage vaccine candidate for malaria. In preparation for clinical […]
ExpreS2ion Biotechnologies will be presenting at the ISBiotech 8th Spring Meeting taking place on March 5-7, 2018 in Norfolk, Virginia, […]
ExpreS2ion Biotechnologies and AdaptVac will be presenting at the free webinar on March 14 at 5PM CET / 4PM GMT […]
Expres2ion Biotechnologies is mentioned in the Swedish newspaper Affärstidningen Näringsliv, in the supplement section “Time to Unite – a Greater […]
ExpreS2ion Biotechnologies is the topic of an article (in Danish) in the business journal MedWatch under the headline “ExpreS2ion-direktør efter […]
Horsholm, Denmark, November 8, 2017 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, […]